Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Graft vs Host Disease 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 102fludarabine phosphate 94Mycophenolic Acid 81Tacrolimus 70Whole-Body Irradiation 65Peripheral Blood Stem Cell Transplantation 65fludarabine 49Busulfan 49Cyclosporine 48Antilymphocyte Serum 44Melphalan 39Filgrastim 37Methotrexate 32Radiotherapy 25Granulocyte Colony-Stimulating Factor 22Cord Blood Stem Cell Transplantation 20Sirolimus 19Rituximab 19thymoglobulin 18Stem Cell Transplantation 18Methylprednisolone 16Alemtuzumab 16Thiotepa 13sargramostim 11Cytarabine 11Cyclosporins 11Clofarabine 11Therapeutics 10Flow Cytometry 10Etoposide 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hodgkin Disease × Maraviroc × Myeloid × Clear all
NCT02208037 2019-01-23

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 2 Completed
279 enrolled 28 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡